NYSEMKT: POASPhaos Technology Holdings Ltd Stock
$0.29-0.02 (-6.45%)
Updated Jul 2, 2026
POAS Price
$0.29
Fair Value Price
N/A
Market Cap
$8.16M
52 Week Low
$0.25
52 Week High
$7.38
P/E
-2.02x
P/B
-2.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$151.33k
Earnings
-$3.56M
Gross Margin
72.1%
Operating Margin
-2,402.13%
Profit Margin
-2,405.5%
Debt to Equity
-1.37
Operating Cash Flow
-$2M
Beta
0.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine POAS's potential to beat the market
- POAS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
POAS
RankedUnranked of 93
RankedUnranked of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.48 | A | |
| $45.43 | A | |
| $31.35 | A |
Be the first to know about important POAS news, forecast changes, insider trades & much more!
POAS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how POAS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
POAS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
POAS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
POAS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more POAS due diligence checks available for Premium users.
Valuation
POAS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.02x
Industry
20.9x
Market
8.54x
POAS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.98x
Industry
3.11x
POAS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
POAS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
POAS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$983.3k
Liabilities
$3.7M
Debt to equity
-1.37
POAS's short-term liabilities ($3.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
POAS's short-term assets ($802.86k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
POAS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
POAS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
POAS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
POAS vs Medical Device Stocks
Phaos Technology Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.